Education
About Us
Working with TipRanks
Follow Us
IRLAB Therapeutics AB Class A (SE:IRLAB.A)
:IRLAB.A
RESEARCH TOOLSreports
IRLAB.A Stock Chart & Stats
Day’s Range― - ―
52-Week Rangekr4.25 - kr18.50
Previous CloseN/A
Volume348.22K
Average Volume (3M)76.13K
Market Cap
kr363.08M
Enterprise Valuekr551.09M
Total Cash (Recent Filing)kr116.88M
Total Debt (Recent Filing)kr5.71M
Price to Earnings (P/E)―
Beta0.28
Next Earnings
May 07, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.60
Shares Outstanding51,788,630
10 Day Avg. Volume14,724
30 Day Avg. Volume76,125
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
―
Mutual Funds
― Other Institutional Investors
99.99% Public Companies and
Individual Investors
IRLAB.A FAQ
What was IRLAB Therapeutics AB Class A’s price range in the past 12 months?
IRLAB Therapeutics AB Class A lowest stock price was kr4.25 and its highest was kr18.50 in the past 12 months.
What is IRLAB Therapeutics AB Class A’s market cap?
IRLAB Therapeutics AB Class A’s market cap is kr363.08M.
When is IRLAB Therapeutics AB Class A’s upcoming earnings report date?
IRLAB Therapeutics AB Class A’s upcoming earnings report date is May 07, 2025 which is in 12 days.
How were IRLAB Therapeutics AB Class A’s earnings last quarter?
IRLAB Therapeutics AB Class A released its earnings results on Feb 12, 2025. The company reported -kr0.104 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.104.
Is IRLAB Therapeutics AB Class A overvalued?
According to Wall Street analysts IRLAB Therapeutics AB Class A’s price is currently Overvalued.
Does IRLAB Therapeutics AB Class A pay dividends?
IRLAB Therapeutics AB Class A does not currently pay dividends.
What is IRLAB Therapeutics AB Class A’s EPS estimate?
IRLAB Therapeutics AB Class A’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does IRLAB Therapeutics AB Class A have?
IRLAB Therapeutics AB Class A has 51,788,630 shares outstanding.
What happened to IRLAB Therapeutics AB Class A’s price movement after its last earnings report?
IRLAB Therapeutics AB Class A reported an EPS of -kr0.104 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.412%.
Which hedge fund is a major shareholder of IRLAB Therapeutics AB Class A?
Currently, no hedge funds are holding shares in SE:IRLAB.A
---
Company Description
IRLAB Therapeutics AB Class A
IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on innovative treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds which aims at offering improved clinical benefit for patients with Parkinson's disease.
---
Technical Analysis
Oncopeptides AB
―
Cantargia AB
―
Guard Therapeutics International AB
―
Immunicum AB
―
Xbrane Biopharma AB
―
---